Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMTX - Immatics N.V


IEX Last Trade
11.1
0.020   0.180%

Share volume: 95,323
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$11.08
0.02
0.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-1.07%
1 Month
-6.65%
3 Months
-1.68%
6 Months
-10.85%
1 Year
-7.58%
2 Year
-11.21%
Key data
Stock price
$11.10
P/E Ratio 
0.00
DAY RANGE
$10.99 - N/A
EPS 
$0.00
52 WEEK RANGE
$7.15 - $13.77
52 WEEK CHANGE
-$0.09
MARKET CAP 
1.142 B
YIELD 
N/A
SHARES OUTSTANDING 
102.985 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
1.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$292,043
AVERAGE 30 VOLUME 
$253,253
Company detail
CEO: Harpreet Singh
Region: US
Website: https://immatics.com/
Employees: 381
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics'​ proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l

Recent news